September 2 (SeeNews) - Bulgarian veterinary drug maker Biovet said on Friday its majority owner Huvepharma and minor shareholder Opportunity 2009 have raised their buyout bid for the remaining 677,998 shares, or 10% of the company, which they do not own to 14.4 levs per share ($8.25/7.36 euro) from 13.3 levs per share offered in July.
Jun 10, 2026
BucharestJun 30, 2026Marrakech
